New York Times -- An unusual internal meeting scheduled for Wednesday at the Food and Drug Administration may signal how agency officials intend to handle the many controversies swirling around its embattled device division.
New York Times -- An unusual internal meeting scheduled for Wednesday at the Food and Drug Administration may signal how agency officials intend to handle the many controversies swirling around its embattled device division.
